- 2023.11.30
Lemzoparlimab CD47
Uliledlimab CD73
Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA, Probody
AI Design, Alphabody
Press Releases
2023.11.06
The Company will have presentations and one-to-one meetings during the upcoming two investor conferences.
2023.11.02
CD38 antibody felzartamab has been granted Breakthrough Therapy Designation by the U.S. FDA, following the Orphan Drug Designation received in May 2023.
2023.11.01
The Company will report preclinical data of givastomig and TJ-L14B, respectively, at the upcoming SITC 2023.
Events